Levosimendan attenuates hypoxia-induced pulmonary hypertension in a porcine model.
Research output: Contribution to journal › Article
BACKGROUND: Levosimendan was hypothesized to attenuate hypoxic pulmonary vasoconstriction (HPV). METHODS: 14 anaesthetized pigs (30,9±1,0kg) were studied in normoxia (FiO2∼0,21) and hypoxia (FiO2∼0,10), before and 10-90 min after infusion of placebo (n=7) or Levosimendan (n=7). RESULTS: Compared to normoxia, hypoxia-baseline at FiO2∼0,10 (n=14) increased PVR by 1.9±0.4 WU (p<0,001), MPAP by 14.3±0.9 mmHg (p<0,001), MRAP by 2.1±0.4 mmHg (p<0,001), PCWP by 1.5±0.3 mmHg (p<0,001), CO by 1.3±0.2 L·min (p<0,001) and HR by 19.9±5.5 beats·min (p<0,001). SVR decreased by 7,2±1.0 WU (p<0,001), MAP and SV remained unaltered (p=ns). Compared to hypoxia-baseline, Levosimendan decreased MPAP and PVR (p<0,05), by ∼9 and ∼19%, respectively, plateauing between 10-90 min. SV increased (p<0,05) by ∼22%, plateauing after 60 min. MRAP, PCWP, HR, CO, MAP, SVR and blood-O2-consumption remained unaltered (p=ns). Compared to hypoxia-baseline, with placebo, MPAP remained stable (p=ns), PVR increased (p<0,05) and CO decreased (p<0,05), by ∼20 and ∼11% after 60-90 and 30-90min, respectively. SV decreased (p<0,05) by ∼8%, plateauing after 60-90min. PCWP and MRAP decreased (p<0,05) by ∼12%, plateauing after 10-60 and 10-90min, respectively. MPAP, HR, MAP, SVR and blood-O2-consumption remained unchanged (p=ns), except at 60min where MAP decreased (p<0,05) by ∼4%. CONCLUSIONS: Levosimendan attenuated HPV and the cardio-depressive effect of sustained hypoxia.
|Research areas and keywords||
Subject classification (UKÄ) – MANDATORY
|Journal||Journal of Cardiovascular Pharmacology|
|Publication status||Published - 2012|
Related research output
Modulators of hypoxic pulmonary vasoconstriction and pulmonary hypertension. Implications for new treatment strategies.KYLHAMMAR, DAVID., 2016, Lund: Lund University: Faculty of Medicine. 86 p.
Research output: Thesis › Doctoral Thesis (compilation)